title: Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004).
abstract: OBJECTIVE
  To evaluate prognostic factors associated with outcome of dogs with multiple cutaneous mast cell tumors (MCTs) treated with surgery with or without adjuvant treatment.
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  54 dogs with a minimum of 2 simultaneous, histologically confirmed cutaneous MCTs that had been excised and had adequate staging and follow-up data.
  
  
  METHODS
  Medical records from 1998 to 2004 were examined. Outcome was assessed with the Kaplan-Meier product-limit method and log-rank analysis. Prognostic factors evaluated included signalment; number, histologic grade, location, size, local recurrence, and de novo development of MCTs; quality of surgical margins; clinical signs at the time of diagnosis; and use of adjuvant treatment.
  
  
  RESULTS
  Medical records of 54 dogs with 153 tumors were included. Median follow-up time was 658 days. Median disease-free interval (1,917 days; range, 11 to 1,917 days) and median survival time (1,917 days; range, 14 to 1,917 days) were not yet reached. The 1- year and 2- to 5-year survival rates were 87% and 85%, respectively. The overall rate of metastasis was 15%. Factors that negatively influenced survival time in the univariate analysis included incomplete excision, local recurrence, size > 3 cm, clinical signs at the time of diagnosis, and use of adjuvant treatment. Presence of clinical signs at the time of diagnosis was the only negative prognostic factor for disease-free interval detected in the multivariate analysis.
  
  
  CONCLUSIONS
  Results suggested that multiple cutaneous MCTs in dogs are associated with a low rate of metastasis and a good prognosis for long-term survival with adequate excision of all MCTs.
authors.affiliation: Animal Cancer Center and Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
authors.forename: Marie N
authors.initials: MN
authors.lastname: Mullins
authors.forename: William S
authors.initials: WS
authors.lastname: Dernell
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Withrow
authors.forename: Eugene J
authors.initials: EJ
authors.lastname: Ehrhart
authors.forename: Douglas H
authors.initials: DH
authors.lastname: Thamm
authors.forename: Susan E
authors.initials: SE
authors.lastname: Lana
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D004285:Dogs; D005260:Female; D008297:Male; D012515:Mast-Cell Sarcoma / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000662:veterinary; D009367:Neoplasm Staging / Q000662:veterinary; D011379:Prognosis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D016896:Treatment Outcome